$9.69
1.48% today
NYSE, Sep 04, 10:00 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$9.83
+0.16 1.65% 1M
-4.52 31.50% 6M
-5.09 34.12% YTD
-12.25 55.48% 1Y
-18.67 65.51% 3Y
-23.42 70.44% 5Y
-23.42 70.44% 10Y
-23.42 70.44% 20Y
NYSE, Closing price Wed, Sep 03 2025
+0.41 4.35%

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$10.9b
Net debt
$8.3b
Cash
$599.0m
Shares outstanding
260.0m
Valuation (TTM | estimate)
P/E
3.7 | 2.5
P/S
0.4 | 0.4
EV/Sales
1.7 | 1.7
EV/FCF
22.5
P/B
3.5
Dividends
DPS
$1.12
Yield 1Y | 5Y
11.4% | 3.1%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
33.6% | 30.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$6.3b | $6.3b
EBITDA
$1.7b | $2.0b
EBIT
$1.4b | $1.7b
Net Income
$700.0m | $1.0b
Free Cash Flow
$482.0m
Growth (TTM | estimate)
Revenue
-1.0% | -1.2%
EBITDA
6.3% | 13.6%
EBIT
2.4% | 17.5%
Net Income
-30.0% | 16.4%
Free Cash Flow
-38.8%
Margin (TTM | estimate)
Gross
56.3%
EBITDA
26.7% | 31.3%
EBIT
21.6%
Net
11.1% | 15.9%
Free Cash Flow
7.7%
Financial Health
Equity Ratio
3.6%
Return on Equity
183.1%
ROCE
12.7%
ROIC
12.3%
Debt/Equity
12.1
More
EPS
$2.7
FCF per Share
$1.9
Short interest
7.4%
Employees
10k
Rev per Employee
$640.0k
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

2x Buy
13%
5x Hold
33%
8x Sell
53%

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

Buy
13%
Hold
33%
Sell
53%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,281 6,281
1% 1%
100%
- Direct Costs 2,747 2,747
5% 5%
44%
3,534 3,534
5% 5%
56%
- Selling and Administrative Expenses 1,765 1,765
6% 6%
28%
- Research and Development Expense 432 432
13% 13%
7%
1,678 1,678
6% 6%
27%
- Depreciation and Amortization 319 319
27% 27%
5%
EBIT (Operating Income) EBIT 1,359 1,359
2% 2%
22%
Net Profit 700 700
30% 30%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
Business Wire
2 days ago
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
Neutral
PRNewsWire
22 days ago
SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@sharehold...
Negative
Seeking Alpha
23 days ago
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside un...
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today